Bruceine A protects against diabetic kidney disease via inhibiting galectin-1.

[1]  R. DeFronzo,et al.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors , 2021, Nature Reviews Nephrology.

[2]  J. Navarro-González,et al.  Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications , 2021, Frontiers in Medicine.

[3]  Seok-Jun Kim,et al.  Galectin-1 accelerates high-fat diet-induced obesity by activation of peroxisome proliferator-activated receptor gamma (PPARγ) in mice , 2021, Cell death & disease.

[4]  G. Núñez,et al.  RACK1 Mediates NLRP3 Inflammasome Activation by Promoting NLRP3 Active Conformation and Inflammasome Assembly. , 2020, Cell reports.

[5]  Shing‐Jong Lin,et al.  Elevated serum galectin-1 concentrations are associated with increased risks of mortality and acute kidney injury in critically ill patients , 2020, PloS one.

[6]  Zhen Wang,et al.  TANK‐binding kinase 1 mediates osteoclast differentiation by regulating NF‐κB, MAPK and Akt signaling pathways , 2020, Immunology and cell biology.

[7]  Xianglin Mei,et al.  Galectins as potential pharmacological targets in renal injuries of diverse etiology. , 2020, European journal of pharmacology.

[8]  D. Serón,et al.  Revisiting Experimental Models of Diabetic Nephropathy , 2020, International journal of molecular sciences.

[9]  D. Bennett,et al.  Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis , 2020, Respiratory Physiology & Neurobiology.

[10]  Po‐Hsun Huang,et al.  Increased circulating galectin-1 levels are associated with the progression of kidney function decline in patients undergoing coronary angiography , 2020, Scientific Reports.

[11]  Yuanyuan Ruan,et al.  RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1. , 2019, Cancer letters.

[12]  D. Owens,et al.  IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. , 2019, Diabetes research and clinical practice.

[13]  Eisuke Kato,et al.  Quassinoids in Brucea javanica are potent stimulators of lipolysis in adipocytes. , 2019, Fitoterapia.

[14]  Jinghong Zhao,et al.  Unraveling LGALS1 as a Potential Immune Checkpoint and a Predictor of the Response to Anti-PD1 Therapy in Clear Cell Renal Carcinoma , 2019, Pathology & Oncology Research.

[15]  R. Nishimura,et al.  Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease , 2019, International journal of molecular sciences.

[16]  S. Liang,et al.  Galectin‐1 is a new fibrosis protein in type 1 and type 2 diabetes , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  Yun Xu,et al.  Cyanidin-3-O-glucoside ameliorates diabetic nephropathy through regulation of glutathione pool. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[18]  J. Lewis,et al.  Update on Diabetic Nephropathy: Core Curriculum 2018. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  Martin Haugmo Iversen,et al.  The Role of Galectins as Modulators of Metabolism and Inflammation , 2018, Mediators of inflammation.

[20]  K. Lam,et al.  Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion , 2018, Clinical Cancer Research.

[21]  Liming Chen,et al.  Triptolide prevents extracellular matrix accumulation in experimental diabetic kidney disease by targeting microRNA‐137/Notch1 pathway , 2018, Journal of cellular physiology.

[22]  M. Fijak,et al.  Galectin-1 enhances TNFα-induced inflammatory responses in Sertoli cells through activation of MAPK signalling , 2018, Scientific Reports.

[23]  C. Cheung,et al.  Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus , 2018, Diabetologia.

[24]  H. Sytwu,et al.  Role of Galectins in Tumors and in Clinical Immunotherapy , 2018, International journal of molecular sciences.

[25]  Yali Zhang,et al.  RACK1 silencing attenuates renal fibrosis by inhibiting TGF-β signaling. , 2017, International journal of molecular medicine.

[26]  A. Kanda,et al.  Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy , 2017, Scientific Reports.

[27]  Y. Miao,et al.  Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. , 2017, Cancer letters.

[28]  R. Shao,et al.  EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells , 2016, Cell Death and Disease.

[29]  J. Borén,et al.  Microdialysis and proteomics of subcutaneous interstitial fluid reveals increased galectin-1 in type 2 diabetes patients. , 2016, Metabolism: clinical and experimental.

[30]  K. Bum-Erdene,et al.  Galectin-1 inhibitors and their potential therapeutic applications: a patent review , 2016, Expert opinion on therapeutic patents.

[31]  Reinhard Windhager,et al.  Galectin-1 Couples Glycobiology to Inflammation in Osteoarthritis through the Activation of an NF-κB–Regulated Gene Network , 2016, The Journal of Immunology.

[32]  Merlin C. Thomas,et al.  Diabetic kidney disease , 2015, Nature Reviews Disease Primers.

[33]  J. Yun,et al.  Targeted inhibition of galectin 1 by thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats , 2015, International Journal of Obesity.

[34]  Lin Sun,et al.  High glucose‐induced Galectin‐1 in human podocytes implicates the involvement of Galectin‐1 in diabetic nephropathy , 2015, Cell biology international.

[35]  K. Bum-Erdene,et al.  Galectin-3 inhibitors: a patent review (2008–present) , 2014, Expert opinion on therapeutic patents.

[36]  Cheng-Ping Yu,et al.  Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer. , 2014, Journal of the American Society of Nephrology : JASN.

[37]  E. Raymond,et al.  Unraveling galectin-1 as a novel therapeutic target for cancer. , 2014, Cancer treatment reviews.

[38]  Z. Ronai,et al.  RACK1 Function in Cell Motility and Protein Synthesis. , 2013, Genes & cancer.

[39]  E. Raymond,et al.  Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. , 2012, Journal of medicinal chemistry.

[40]  Riyao Yang,et al.  Galectins in acute and chronic inflammation , 2012, Annals of the New York Academy of Sciences.

[41]  P. Collins,et al.  Taloside Inhibitors of Galectin‐1 and Galectin‐3 , 2012, Chemical biology & drug design.

[42]  F. Cedeno-Laurent,et al.  Galectin-1 research in T cell immunity: past, present and future. , 2012, Clinical immunology.

[43]  C. Zeng,et al.  Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  Li Pan,et al.  NF-κB Inhibitors from Brucea javanica Exhibiting Intracellular Effects on Reactive Oxygen Species , 2010 .

[45]  Elena Ermakova,et al.  Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity. , 2010, Journal of molecular biology.

[46]  Hongjian Jiang,et al.  Bruceine A , 2010, Acta Crystallographica Section E.

[47]  Rohit R. Ghurye,et al.  Galectin-1 stimulates monocyte chemotaxis via the p44/42 MAP kinase pathway and a pertussis toxin-sensitive pathway. , 2009, Glycobiology.

[48]  J. Hirabayashi,et al.  Expression of galectin-1, a new component of slit diaphragm, is altered in minimal change nephrotic syndrome , 2009, Laboratory Investigation.

[49]  D. Ferenbach,et al.  Macrophages and dendritic cells: what is the difference? , 2008, Kidney international.

[50]  R. Kiss,et al.  Galectin-1: a small protein with major functions. , 2006, Glycobiology.

[51]  M. Mohammadi,et al.  Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. , 2018, Kidney international.

[52]  T. Coffman,et al.  Modelling diabetic nephropathy in mice , 2018, Nature Reviews Nephrology.

[53]  H. Matsuura,et al.  Antitrypanosomal activities of acetylated bruceines A and C; a structure–activity relationship study , 2011, Journal of Natural Medicines.

[54]  Subeki,et al.  Evaluation of efficacy of bruceine A, a natural quassinoid compound extracted from a medicinal plant, Brucea javanica, for canine babesiosis. , 2009, The Journal of veterinary medical science.